MSD, known as Merck outside the United States and Canada, will host its second-quarter 2024 sales and earnings conference call for institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 30. During the call, company executives will provide…
UCB, a global biopharmaceutical company, has unveiled new research findings supporting its recently launched treatments in the generalized myasthenia gravis (gMG) portfolio. These findings will be presented at the 10th Congress of the European Academy of Neurology (EAN) from June…
Roche’s PiaSky Receives Positive CHMP Opinion for PNH Treatment in EU Today, Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended PiaSky® (crovalimab) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH). PiaSky,…
Roche announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for extending the marketing authorization of Vabysmo® (faricimab) to include the treatment of visual impairment due to macular edema…
AbbVie announced today the acquisition of Celsius Therapeutics, Inc. (“Celsius”), a privately held biotechnology company pioneering new therapies for inflammatory diseases. Celsius’ lead investigational asset, CEL383, is a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study…
As the world’s largest pure-play consumer health company by revenue, Kenvue has released its first-ever Healthy Lives Mission Report, highlighting the company’s efforts to enhance the well-being of both people and the planet in 2023. “We recognize that human health…
Bayer AG and Charité – Universitätsmedizin Berlin Unveil Plans for Berlin Center Advancing Gene and Cell Therapies Today, Bayer AG and Charité – Universitätsmedizin Berlin announced their joint initiative to establish the Berlin Center for Gene and Cell Therapies, bolstered…
Takeda today announced positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized…
Today, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for KRAZATI® (adagrasib) in combination with cetuximab. This targeted treatment is for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC),…
Bristol Myers Squibb announced today that the European Medicines Agency (EMA) has validated its application to introduce a new subcutaneous administration route for Opdivo® (nivolumab). This includes a new pharmaceutical form (solution for injection) and a new strength (600 mg/vial)…
Actylis, a prominent global manufacturer and sourcing expert specializing in critical materials and performance ingredients for life sciences and specialty chemicals, has appointed Scott Thomson as its new Chief Executive Officer. Thomson brings over thirty years of experience in the…
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced today the latest efficacy and safety updates from the Phase 1/2 trial of SAR443579/IPH6101 (SAR’579), a CD123 targeting NKp46/CD16-based Natural Killer Cell Engager (NKCE). The results were presented at the European…